The 2026 paper reports no trial results yet because it publishes the methods for a planned phase-2 double-blind randomized trial with four parallel arms. For adults with persistent acne, it outlines a hypothesis about oral probiotics and topical secretome added to standard therapy, not a proven treatment.
Persistent acne vulgaris means acne that begins in adolescence and continues into adulthood. Secretome here means the topical study product tested alongside standard care, while probiotics are the oral study product. As BMJ Open describes in the published protocol in BMJ Open, the trial design comes before any patient results.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the trial plans to test
- How improvement will be measured
- Who this research concerns
- What to do until results appear
What the trial plans to test
The plan tests oral probiotics and topical secretome, alone and together, added to standard acne therapy. Each arm keeps standard treatment as the base and changes only the added study products. The tested idea is that the additions improve outcomes by limiting virulent Cutibacterium acnes types, restoring microbial diversity, and supporting barrier repair.
Cutibacterium acnes means a skin bacterium linked to acne, and virulent types means strains more likely to drive inflammation. For readers, the key point is add-on use. The paper does not present probiotics or secretome as replacements for standard care.
How improvement will be measured
The planned primary outcome is fewer comedones and fewer inflammatory papules and pustules. Comedones means clogged pores, including blackheads and whiteheads, while papules and pustules mean red bumps and pus-filled spots. Counting will use YOLOv8 machine-learning lesion detection plus acne-severity grading.
YOLOv8 means image software that finds and counts lesions in photos, giving a more objective count than visual guesswork. BMJ Open lists this measurement plan in the trial methods in BMJ Open. A photo-based count helps compare arms fairly. It does not change care now because no counts or scores have been reported.
Who this research concerns
The relevant group is people with persistent acne vulgaris that started in the teen years and continued into adult life. The Dove Medical Press review of adult acne describes this pattern in the adult-onset acne review from Dove Medical Press, most often studied in adult women age 25 and older. That focus matters because adult persistence brings different concerns than brief teen breakouts.
Ongoing lesions can affect work photos, makeup choices, shaving comfort, and scarring risk. The protocol itself supplies methods only, so it supplies no efficacy results, safety data, or subgroup findings for these adults. Readers cannot yet tell benefit size, best strain or dose, or who responds.
What to do until results appear
Current practical care remains guideline-based standard therapy, often in combination. The American Academy of Dermatology guidance summarized via Newswise points to established options in the Academy acne guidelines summarized by Newswise.
Use the waiting period to track lesions, triggers, periods, products, and side effects. Bring that log plus your current regimen to your next dermatology visit to review combination options.
- Benzoyl peroxide to reduce acne bacteria
- Topical retinoids such as adapalene or tretinoin
- Oral doxycycline when indicated, often paired with topical treatment
You Might Also Like
- The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: What the Research Means for Adults With Persistent Acne
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: What the Research Means for Adults With Persistent Acne
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: What the Research Means for Adults With Persistent Acne